# EDGAR Filing Document

**Accession Number:** 0001746466
**File Stem:** 0001193125-26-248246
**Filing Date:** 2026-5
**Character Count:** 9937
**Document Hash:** eddcff520f9501a09018b344496970d6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-248246.hdr.sgml**: 20260529

**ACCESSION NUMBER**: 0001193125-26-248246

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260528

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260529

**DATE AS OF CHANGE**: 20260529

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Equillium, Inc.
- **CENTRAL INDEX KEY:** 0001746466
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 821554746
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38692
- **FILM NUMBER:** 261044307

**BUSINESS ADDRESS:**
- **STREET 1:** 2223 AVENIDA DE LA PLAYA
- **STREET 2:** SUITE 105
- **CITY:** LA JOLLA
- **STATE:** CA
- **ZIP:** 92037
- **BUSINESS PHONE:** (858) 412-5302

**MAIL ADDRESS:**
- **STREET 1:** 2223 AVENIDA DE LA PLAYA
- **STREET 2:** SUITE 105
- **CITY:** LA JOLLA
- **STATE:** CA
- **ZIP:** 92037

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): May 28, 2026

## Equillium, Inc.

#### (Exact name of Registrant as Specified in Its Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-38692** | **82-1554746** |
| **(State or Other Jurisdiction**<br> **of Incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| **2223 Avenida de la Playa** |  |
| **Suite 105** |  |
| **La Jolla, CA** | **92037** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

#### Registrant's Telephone Number, Including Area Code: (858) 240-1200
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange**<br> **on which registered** |
| Common Stock, par value $0.0001 per share | EQ | The Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 5.07** | **Submission of Matters to a Vote of Security Holders.**  |

---

On May 28, 2026, Equillium, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting"). As of April 1, 2026, the record date for the Annual Meeting (the "Record Date"), 63,226,556 shares of the Company's common stock were outstanding and entitled to vote at the Annual Meeting. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below.

A total of 54,287,329 shares of the Company's common stock were present at the Annual Meeting or represented by proxy, which represents approximately 85.86% of the shares of the Company's common stock outstanding as of the Record Date.

#### Proposal 1. Election of directors.
The Company's stockholders elected the two persons listed below as Class II directors, each to serve until the Company's 2029 Annual Meeting of Stockholders and until their respective successor has been duly elected and qualified, or until their earlier death, resignation or removal. Former director Peter Colabuono was not renominated as a director and his term ended at the Annual Meeting. In connection with the expiration of Mr. Colabuono's term, the Company reduced the size of the Board of Directors from seven directors to six directors. The final voting results are as follows:

---

| | | | |
|:---|:---|:---|:---|
| Name | Votes For | Votes Withheld | Broker Non-<br>Votes |
|  Charles McDermott | 36072238 | 10018889 | 8196202 |
|  Bruce Steel | 45955052 | 136075 | 8196202 |

---

#### Proposal 2. Approval of an amendment to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split.
The Company's stockholders approved an amendment to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company's common stock at a ratio in the range of 1-for-2 to 1-for-20, inclusive, with such ratio to be determined in the discretion of the Company's Board of Directors and with such reverse stock split to be effected at such time and date, if at all, as determined by the Company's Board of Directors in its sole discretion. The final voting results are as follows:

---

| | | | |
|:---|:---|:---|:---|
| Votes For | Votes Against | Abstentions | Broker Non-Votes |
| 52697618 | 1559976 | 29735 | 0 |

---

#### Proposal 3. Ratification of the appointment of the independent registered public accounting firm.
The Company's stockholders ratified the appointment by the Audit Committee of the Company's Board of Directors of Crowe LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows:

---

| | | | |
|:---|:---|:---|:---|
| Votes For | Votes Against | Abstentions | Broker Non-Votes |
| 54274675 | 5234 | 7420 | 0 |

---

#### Proposal 4. Approval of an amendment to the Company's Amended and Restated Certificate of Incorporation.
The Company's stockholders approved an amendment to the Company's Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 200,000,000 to 400,000,000 shares. The final voting results are as follows:

---

| | | | |
|:---|:---|:---|:---|
| Votes For | Votes Against | Abstentions | Broker Non-Votes |
| 42687545 | 11570307 | 29477 | 0 |

---

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.**  |

---

(d) Exhibits

---

| | |
|:---|:---|
| 3.1 | [Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Company, dated May 28, 2026.](d148127dex31.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

#### SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **EQUILLIUM, INC.** | **EQUILLIUM, INC.** |
| Date: May 29, 2026 | By: | */s/ Bruce D. Steel* |
|  |  | Bruce D. Steel |
|  |  | Chief Executive Officer |

---

## Exhibit 3.1

**Exhibit 3.1** 

**CERTIFICATE OF AMENDMENT OF THE** 

**AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF EQUILLIUM, INC.** 

**EQUILLIUM, INC.,** a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows:

**FIRST:** The name of this corporation is Equillium, Inc. (the "Company").

**SECOND:** The date on which the Company's Certificate of Incorporation was originally filed with the Secretary of State of the State of Delaware is March 16, 2017. The Company was originally incorporated under the name Attenuate Biopharmaceuticals, Inc.

**THIRD**: The Board of Directors of the Company, acting in accordance with the provisions of Sections 141 and 242 of the General Corporation Law of the State of Delaware, adopted resolutions amending its Amended and Restated Certificate of Incorporation, as heretofore amended (the "Certificate of Incorporation"), as follows:

1. The Certificate of Incorporation is hereby amended by deleting Article IV Section A thereof and inserting the following in lieu thereof:

"**A**. The Company is authorized to issue two classes of stock to be designated, respectively, "***Common Stock***" and "***Preferred Stock***." The total number of shares which the Company is authorized to issue is 410,000,000 shares. 400,000,000 shares shall be Common Stock, each having a par value of $0.0001. 10,000,000 shares shall be Preferred Stock, each having a par value of $0.0001."

**FOURTH:** The foregoing amendment was submitted to the stockholders of the Company for their approval, and was duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware and shall be effective as of 5:00 p.m., Eastern time, on the business day following the filing of this Certificate of Amendment with the office of the Secretary of State of the State of Delaware.

**IN WITNESS** **WHEREOF, EQUILLIUM** **, INC.** has caused this Certificate of Amendment to be signed by its Chief Executive Officer this 28th day of May, 2026.

---

| | |
|:---|:---|
| **EQUILLIUM, INC.** | **EQUILLIUM, INC.** |
| By: | /s/ Bruce D. Steel |
|  | Bruce D. Steel |
|  | Chief Executive Officer |

---